Kindly find the enclosed herewith the Audited Standalone Financial Results of the Company for the fourth quarter and year ended on 31st March 2025 of the financial year 2024-25 as approved ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 8.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
BDH Industries reported FY25 revenue from operations of ₹6,650.83 lakhs, down about 22.5% from ₹8,583.10 lakhs in FY24, with Q4 revenue falling to ₹1,782.16 lakhs from ₹2,710.82 lakhs a year ago. Profit after tax for the year came in at ₹927.33 lakhs versus ₹986.78 lakhs, a decline of roughly 6%, translating to EPS of ₹16.11 against ₹17.14. Despite the top-line slip, the company remained debt-light, cutting borrowings sharply from ₹869.07 lakhs to ₹97.97 lakhs and boosting cash balances to ₹3,115.79 lakhs, while operating cash flow turned strongly positive at ₹1,477.09 lakhs (from negative ₹186.98 lakhs last year). The board has recommended a dividend of ₹4.50 per share and reappointed both Managing Directors, with the auditor CLB & Associates issuing an unmodified opinion.
Lower revenue and profits year-on-year may weigh on the stock, but the stronger balance sheet, debt reduction, healthy cash generation and continued dividend should reassure shareholders about the company's financial stability.